Organon & Co | OGN - Current Assets


Organon & Co reported $4.7B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Celltrion KRW 5.54T 291.68B Sep/2025
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 409.44M 4.39M Dec/2025
Divis Laboratories Ltd INR 98.43B 2.38B Sep/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Kangmei Pharma CNY 7.03B 128.34M Sep/2025
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Organigram Holdings CAD 256.54M 28.35M Dec/2025
Organon & Co USD 4.7B 82M Sep/2025
Ovoca Bio EUR 1.56M 3.39M Jun/2025
Pharma Mar EUR 283.41M 40.53M Dec/2025
Qiagen NV USD 2B 535.87M Dec/2025
Sartorius EUR 1.72B 449M Sep/2025
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.67B 950.94M Dec/2025